Research Use — strictly for laboratory only and are not for human or veterinary use
Why We Started With Just Four Peptides
DR Korea Group began with four carefully selected research peptides
GHK-Cu, BPC-157, TB-500 MOTS-c, and Tesamorelin — because they represent key areas of modern regenerative peptide research: skin regeneration, tissue repair, cellular recovery, mitochondrial function and metabolic resilience.
Our scientific focus is based on a simple principle: cellular stress, inflammation and mitochondrial decline often begin before visible ageing, reduced performance or tissue degeneration appear. By studying peptides involved in collagen synthesis, extracellular matrix remodelling, angiogenesis, wound-healing biology and cellular energy regulation, we aim to support a deeper understanding of how the body maintains repair and resilience.
Glow Research
Glow™ Peptide
Scientific Overview of a Multi-Peptide Research Formulation for Skin Regeneration and Tissue Repair
Glow™ is a proprietary research peptide formulation developed to explore the combined biological properties of three extensively studied regenerative peptides: GHK-Cu (Copper Tripeptide-1), BPC-157 (Body Protection Compound-157), and TB-500 (Thymosin Beta-4 fragment). Each peptide has been investigated independently for its potential role in tissue repair, extracellular matrix remodelling, wound-healing biology, cellular signalling, and regenerative medicine.
Although these peptides act through different biological pathways, current preclinical research suggests that they may influence complementary mechanisms involved in tissue maintenance, inflammatory regulation, collagen synthesis, angiogenesis, and cellular migration. As a result, they have become subjects of growing scientific interest within regenerative biology, aesthetic research, sports medicine, and biomaterials science.
GHK-Cu: Skin Regeneration and Extracellular Matrix Biology
Among the three components, GHK-Cu possesses the strongest body of evidence relating to skin biology. Naturally present in human plasma and released during tissue injury, this endogenous copper-binding tripeptide functions as an important cellular signalling molecule involved in tissue remodelling.
Experimental and cosmetic dermatology research suggests that GHK-Cu may stimulate fibroblast activity, collagen production, elastin synthesis, glycosaminoglycan formation, and angiogenesis while influencing multiple genes associated with tissue repair. These mechanisms have led to extensive investigation of GHK-Cu in topical skin applications, where studies have reported improvements in skin elasticity, hydration, dermal density, wrinkle appearance, and recovery following environmental damage.
Beyond dermatology, laboratory studies have demonstrated antioxidant, anti-inflammatory and extracellular matrix remodelling properties, supporting continued investigation into its broader regenerative potential. Nevertheless, many published cosmetic studies remain relatively small or industry-sponsored, and systemic therapeutic applications require substantially stronger clinical evidence before conclusions can be drawn.
BPC-157: Experimental Tissue Repair
BPC-157 is a synthetic pentadecapeptide originally derived from gastric proteins and has become one of the most widely investigated regenerative peptides in experimental musculoskeletal research. Animal studies have demonstrated accelerated tendon healing, ligament repair, skeletal muscle regeneration, bone recovery, peripheral nerve healing, and gastrointestinal tissue protection.
Several mechanisms have been proposed, including stimulation of angiogenesis through vascular endothelial growth factor (VEGF) signalling, modulation of nitric oxide pathways, enhanced fibroblast migration, collagen deposition, and regulation of inflammatory cytokines. These biological effects suggest a potential role in supporting natural tissue repair processes.
However, despite encouraging laboratory findings, high-quality human clinical trials remain limited, and current evidence is insufficient to establish efficacy, optimal dosing protocols, or long-term safety in clinical practice.
TB-500: Cellular Migration and Tissue Remodelling
TB-500 is a synthetic fragment derived from thymosin beta-4, a naturally occurring peptide involved in embryonic development, wound healing, cytoskeletal organisation, and cellular migration.
Preclinical research has demonstrated that thymosin beta-4 may regulate actin dynamics, promote endothelial cell migration, stimulate angiogenesis, reduce inflammatory responses, and support collagen organisation during tissue repair. Animal studies have reported improvements in tendon, ligament, muscle, skin, cardiac and corneal healing.
Although these biological findings are promising, human clinical evidence specific to TB-500 remains extremely limited. Most available research has been conducted in laboratory and animal models, highlighting the need for robust randomised clinical trials before therapeutic conclusions can be established.
Scientific Perspective
The rationale behind Glow™ lies in combining peptides that have been independently investigated for different aspects of regenerative biology. GHK-Cu contributes substantial evidence relating to skin regeneration and extracellular matrix remodelling, while BPC-157 and TB-500 have demonstrated complementary regenerative mechanisms in preclinical models involving connective tissue repair, angiogenesis and inflammatory regulation.
Current research suggests that these peptides influence multiple cellular pathways involved in collagen synthesis, fibroblast activation, tissue remodelling and wound-healing biology. However, the majority of evidence supporting combination approaches remains experimental, and well-designed human clinical studies evaluating this specific formulation have not yet been performed.
Glow™ should therefore be understood as a research formulation developed to explore advances in peptide science rather than as an established therapeutic intervention.
- Ahmed, M.R. et al. (2005) Journal of the Peripheral Nervous System, 10(1), pp.17–30.
- Badenhorst, T. et al. (2016) Journal of Aging Science, 4(2), Article 166.
- Campbell, J.D. et al. (2012) Genome Medicine, 4, Article 67.
- Canapp, S.O. Jr. et al. (2003) Veterinary Surgery, 32(6), pp.515–523.
- DeFoor, M.T. and Dekker, T.J. (2025) Arthroscopy, 41(2), pp.150–152.
- Goldstein, A.L., Hannappel, E. and Kleinman, H.K. (2005) Trends in Molecular Medicine, 11(9), pp.421–429.
- Huang, P.J. et al. (2007) Photomedicine and Laser Surgery, 25(3), pp.183–190.
- Maquart, F.X. et al. (1988) FEBS Letters, 238(2), pp.343–346.
- Pickart, L. (2008) Journal of Biomaterials Science, Polymer Edition, 19(8), pp.969–988.
- Pickart, L., Vasquez-Soltero, J.M. and Margolina, A. (2014) BioMed Research International, Article ID 151479.
- Pickart, L., Vasquez-Soltero, J.M. and Margolina, A. (2015) BioMed Research International, Article ID 648108.
- Rahman, O.F., Lee, S.J. and Seeds, W.A. (2026) Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews, 10(1), e25.00236.
- Seiwerth, S. et al. (2018) Current Pharmaceutical Design, 24(18), pp.1972–1989.
- Siméon, A. et al. (1999) Journal of Investigative Dermatology, 112(6), pp.957–964.
- Siméon, A. et al. (2000) Journal of Investigative Dermatology, 115(6), pp.962–968.
- Vasireddi, N. et al. (2025) HSS Journal. Online ahead of print.
- Wegrowski, Y., Maquart, F.X. and Borel, J.P. (1992) Life Sciences, 51(13), pp.1049–1056.
GHK-cu
Scientific Overview of a Copper Peptide in Skin Regeneration and Tissue Repair
GHK-Cu exerts its biological activity through multiple complementary mechanisms that distinguish it from many other regenerative peptides. As a naturally occurring copper transporter, GHK-Cu facilitates the delivery of bioavailable copper, an essential trace element required for numerous enzymatic reactions involved in collagen maturation, antioxidant defence, connective tissue integrity and cellular metabolism. Beyond copper transport, GHK-Cu also functions as a powerful signalling peptide capable of regulating gene expression involved in tissue repair and cellular homeostasis.
One of the best-characterised effects of GHK-Cu is its influence on the extracellular matrix (ECM). Laboratory studies have consistently demonstrated increased synthesis of collagen types I and III, elastin, decorin and sulfated glycosaminoglycans following GHK-Cu exposure. These extracellular matrix components are essential for maintaining skin strength, elasticity, hydration and structural integrity. In vitro studies have also shown enhanced fibroblast proliferation and migration, supporting tissue remodelling during wound healing and normal skin maintenance.
Research further suggests that GHK-Cu promotes angiogenesis, the formation of new blood vessels that improves oxygen and nutrient delivery to damaged tissues. Experimental models additionally demonstrate modulation of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs), helping regulate balanced extracellular matrix remodelling while reducing excessive tissue degradation. These mechanisms collectively contribute to improved wound repair and restoration of normal tissue architecture.
Perhaps the most significant advance in recent years has been the discovery that GHK-Cu influences gene expression. Genomic analyses have demonstrated that the peptide regulates thousands of human genes associated with inflammation, oxidative stress, DNA repair, stem cell activity, cellular differentiation and tissue regeneration. One particularly notable investigation reported that GHK partially reversed a gene-expression signature associated with emphysema in laboratory models while improving collagen remodelling in fibroblasts derived from patients with chronic obstructive pulmonary disease (COPD). Although scientifically important, these findings represent molecular and cellular observations rather than evidence of clinical efficacy for pulmonary disease.
Scientific Perspective
Within dermatology, GHK-Cu possesses the strongest translational evidence among regenerative peptides. Clinical and cosmetic studies have reported improvements in skin firmness, elasticity, hydration, dermal density and wrinkle appearance following topical application. Additional investigations suggest enhanced recovery following environmental skin damage and cosmetic procedures through improved collagen remodelling and accelerated wound healing. However, many available cosmetic studies involve relatively small sample sizes or industry sponsorship, and further independent, large-scale randomised trials would strengthen the current evidence base.
Preclinical research also describes antioxidant, anti-inflammatory, neuroprotective and tissue-remodelling properties across several organ systems, including skin, peripheral nerves, connective tissue and the gastrointestinal tract. Nevertheless, despite encouraging experimental findings, evidence supporting injectable or systemic GHK-Cu for anti-ageing, regenerative medicine or internal therapeutic applications remains limited. Current orthopaedic and regenerative medicine reviews conclude that while GHK-Cu demonstrates considerable biological promise, high-quality human clinical studies are still required to establish efficacy, dosing strategies and long-term safety beyond topical use.
Overall, GHK-Cu represents one of the most extensively studied regenerative peptides currently available, with substantial evidence supporting its role in skin regeneration, extracellular matrix remodelling, collagen synthesis and wound-healing biology. Its combination of copper transport, gene-expression modulation and tissue repair mechanisms makes it a valuable subject of ongoing regenerative research. However, broader therapeutic applications should continue to be regarded as investigational until supported by rigorous clinical evidence.
- Ahmed, M.R., Basha, S.H., Gopinath, D., Muthusamy, J. and Jayakumar, R. (2005) ‘Initial upregulation of growth factors and inflammatory mediators during nerve regeneration in the presence of cell adhesive peptide-incorporated collagen tubes’, Journal of the Peripheral Nervous System, 10(1), pp. 17–30.
- Badenhorst, T., Svirskis, D., Merrilees, M., Bolke, L. and Wu, Z. (2016) ‘Effects of GHK-Cu on MMP and TIMP expression, collagen and elastin production, and facial wrinkle parameters’, Journal of Aging Science, 4(2), Article 166.
- Campbell, J.D., McDonough, J.E., Zeskind, J.E., Hackett, T.L., Pechkovsky, D.V., Brandsma, C.A., Suzuki, M., Gosselink, J.V., Liu, G., Alekseyev, Y.O. et al. (2012) ‘A gene expression signature of emphysema-related lung destruction and its reversal by the tripeptide GHK’, Genome Medicine, 4, Article 67.
- Canapp, S.O. Jr., Farese, J.P., Schultz, G.S., Gowda, S., Ishak, A.M., Swaim, S.F., Vangilder, J. and Lee-Ambrose, L. (2003) ‘The effect of topical tripeptide-copper complex on healing of ischemic open wounds’, Veterinary Surgery, 32(6), pp. 515–523.
- Huang, P.J., Huang, Y.C., Su, M.F., Yang, T.Y., Huang, J.R. and Jiang, C.P. (2007) ‘In vitro observations on the influence of copper peptide aids for LED photoirradiation of fibroblast collagen synthesis’, Photomedicine and Laser Surgery, 25(3), pp. 183–190.
- Kang, Y.A., Choi, H.R., Na, J.I., Huh, C.H., Kim, M.J., Youn, S.W., Kim, K.H. and Park, K.C. (2009) ‘Copper-GHK increases integrin expression and p63 positivity by keratinocytes’, Archives of Dermatological Research, 301(4), pp. 301–306.
- Maquart, F.X., Loren Pickart, Laurent, M., Gillery, P., Monboisse, J.C. and Borel, J.P. (1988) ‘Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu²⁺’, FEBS Letters, 238(2), pp. 343–346.
- Loren Pickart (2008) ‘The human tri-peptide GHK and tissue remodeling’, Journal of Biomaterials Science, Polymer Edition, 19(8), pp. 969–988.
- Loren Pickart, Vasquez-Soltero, J.M. and Margolina, A. (2014) ‘GHK and DNA: Resetting the human genome to health’, BioMed Research International, 2014, Article ID 151479.
- Loren Pickart, Vasquez-Soltero, J.M. and Margolina, A. (2015) ‘GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration’, BioMed Research International, 2015, Article ID 648108.
- Loren Pickart, Vasquez-Soltero, J. and Margolina, A. (2017) ‘The effect of the human peptide GHK on gene expression relevant to nervous system function and cognitive decline’, Brain Sciences, 7(2), Article 20.
- Siméon, A., Monier, F., Emonard, H., Gillery, P., Birembaut, P., Hornebeck, W. and Maquart, F.X. (1999) ‘Expression and activation of matrix metalloproteinases in wounds: Modulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu²⁺’, Journal of Investigative Dermatology, 112(6), pp. 957–964.
- Siméon, A., Wegrowski, Y., Bontemps, Y. and Maquart, F.X. (2000) ‘Expression of glycosaminoglycans and small proteoglycans in wounds: Modulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu²⁺’, Journal of Investigative Dermatology, 115(6), pp. 962–968.
- Wegrowski, Y., Maquart, F.X. and Borel, J.P. (1992) ‘Stimulation of sulfated glycosaminoglycan synthesis by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu²⁺’, Life Sciences, 51(13), pp. 1049–1056.
MOTS - C Research
MOTS-c: Scientific Overview of a Mitochondrial-Derived Peptide in Metabolic and Cellular Research
MOTS-c represents one of the most extensively studied mitochondrial-derived peptides in modern metabolic research. Unlike traditional peptide hormones produced by endocrine tissues, MOTS-c is synthesised within mitochondria and released as an intracellular signalling peptide capable of influencing gene expression and metabolic adaptation. This unique biology has positioned MOTS-c as an important research target for understanding mitochondrial communication, healthy ageing, and cellular resilience.
One of the principal biological mechanisms proposed for MOTS-c involves activation of the AMP-activated protein kinase (AMPK) pathway, often described as one of the body’s primary metabolic energy sensors. AMPK regulates glucose uptake, fatty acid oxidation, mitochondrial biogenesis, and cellular energy balance. Experimental studies have demonstrated that MOTS-c activates AMPK during periods of metabolic stress, encouraging cells to increase energy efficiency while reducing metabolic dysfunction.
Preclinical research has also shown that MOTS-c influences insulin sensitivity by promoting glucose utilisation within skeletal muscle and reducing metabolic stress associated with obesity and ageing. Animal studies have reported improvements in exercise capacity, physical endurance, mitochondrial function, body composition, and metabolic flexibility following MOTS-c administration. These observations have generated interest in its potential application within exercise physiology, healthy ageing research, and metabolic disorders.
Additional laboratory investigations suggest that MOTS-c participates in the regulation of oxidative stress and inflammatory signalling. Experimental models have demonstrated reduced production of reactive oxygen species, improved mitochondrial quality control, enhanced cellular stress resistance, and activation of genes involved in antioxidant defence. These findings support the hypothesis that MOTS-c contributes to maintaining mitochondrial health and protecting cells during periods of physiological stress. However, these mechanisms continue to be actively investigated and remain incompletely understood.
Emerging human research has provided encouraging but preliminary evidence. Early clinical studies have identified associations between circulating MOTS-c concentrations and metabolic health, insulin sensitivity, physical fitness, and ageing. Some investigations have observed lower endogenous MOTS-c levels in individuals with obesity or metabolic disease compared with healthy controls, suggesting a possible physiological role in metabolic regulation. Nevertheless, intervention studies evaluating exogenous MOTS-c administration remain limited, and there is currently insufficient evidence to establish clinical efficacy or therapeutic protocols.
Despite growing scientific interest, important limitations remain. Current knowledge regarding optimal dosage, pharmacokinetics, long-term safety, treatment duration, and clinical outcomes is incomplete. Most published studies continue to rely on animal models or laboratory experiments, and relatively few large randomised controlled human trials have been completed. Consequently, regulatory authorities have not approved MOTS-c for the treatment of metabolic disease, obesity, age-related disorders, or athletic performance enhancement.
Overall, MOTS-c represents a promising area of mitochondrial and regenerative research with substantial experimental evidence supporting its role in metabolic regulation, cellular energy homeostasis, mitochondrial function, and healthy ageing biology. Its unique origin within the mitochondrial genome distinguishes it from most therapeutic peptides currently under investigation. However, while the biological mechanisms are increasingly well characterised, translation into routine clinical practice requires considerably more high-quality human research. At present, MOTS-c should be regarded as an investigational peptide whose potential continues to be explored through ongoing scientific study rather than an established therapeutic intervention.
- Cobb, L.J. et al. (2016) ‘Naturally occurring mitochondrial-derived peptides are age-dependent regulators of apoptosis, insulin sensitivity and inflammatory markers’, Aging, 8(4), pp. 796–809.
- Lee, C. et al. (2015) ‘The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance’, Cell Metabolism, 21(3), pp. 443–454.
- Lu, H. et al. (2019) ‘MOTS-c peptide regulates stress responses, metabolic flexibility and physical capacity’, Proceedings of the National Academy of Sciences, 116(47), pp. 23491–23501.
- Reynolds, J.C. et al. (2021) ‘Mitochondrial-derived peptide MOTS-c is an exercise-induced regulator of metabolic homeostasis and physical performance’, Nature Communications, 12, Article 470.
- Yen, K., Lee, C. and Cohen, P. (2020) ‘The emerging biology of mitochondrial-derived peptides’, Nature Reviews Endocrinology, 16(9), pp. 480–490.
- Zhang, J., Linton, J.N. et al. (2025) Injectable Therapeutic Peptides: Applications in Regenerative Medicine and Sports Performance. American Journal of Sports Medicine. Narrative Review.
- Rahman, O.F., Lee, S.J. and Seeds, W.A. (2026) Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews, 10(1), e25.00236.
Tesamorelin
Scientific Overview of a Growth Hormone-Releasing Hormone Analogue in Metabolic and Regenerative Research
Tesamorelin functions by selectively binding to growth hormone-releasing hormone receptors located within the anterior pituitary gland, stimulating pulsatile secretion of endogenous growth hormone. Increased circulating GH subsequently enhances hepatic production of IGF-1, a key anabolic growth factor involved in protein synthesis, cellular proliferation, tissue maintenance, and metabolic regulation. Because physiological feedback mechanisms remain intact, endogenous hormone release is more tightly regulated than with direct recombinant growth hormone administration.
The most robust clinical evidence for tesamorelin relates to visceral adipose tissue reduction. Multiple placebo-controlled clinical trials involving adults with HIV-associated lipodystrophy have demonstrated significant reductions in abdominal visceral fat while largely preserving subcutaneous fat mass. These improvements were accompanied by favourable changes in lipid metabolism, including reductions in triglyceride concentrations and modest improvements in cardiovascular risk markers. Importantly, lean body mass was generally maintained throughout treatment, suggesting that tesamorelin selectively influences metabolically active visceral fat rather than producing generalised weight loss.
Beyond body composition, emerging research has explored tesamorelin’s effects on liver health. Clinical studies in patients with HIV-associated non-alcoholic fatty liver disease (NAFLD) demonstrated reductions in hepatic fat accumulation and improvements in several biomarkers associated with liver fibrosis. These findings have generated interest in understanding whether growth hormone signalling may influence hepatic metabolism and inflammatory pathways, although further investigation is required before broader clinical conclusions can be reached.
Additional experimental research has investigated the relationship between tesamorelin, healthy ageing, and cognitive function. Early clinical studies have reported modest improvements in certain cognitive parameters among older adults with age-related cognitive decline, potentially through IGF-1-mediated effects on neuronal plasticity and neurovascular function. However, these studies remain relatively small, and evidence is insufficient to support routine clinical use for neurodegenerative disorders or cognitive enhancement.
Within musculoskeletal medicine, biological rationale exists because growth hormone and IGF-1 contribute to muscle protein synthesis, connective tissue turnover, bone metabolism, and tissue repair. Nevertheless, contemporary orthopaedic reviews conclude that there is currently no direct clinical evidence supporting tesamorelin for tendon healing, ligament regeneration, cartilage repair, or sports injury recovery. Most regenerative claims originate from indirect physiological mechanisms rather than controlled human trials evaluating musculoskeletal outcomes.
Tesamorelin has been generally well tolerated within approved clinical studies. The most commonly reported adverse events include injection-site reactions, mild peripheral oedema, arthralgia, transient glucose metabolism changes, and increased circulating IGF-1 concentrations. Because growth hormone signalling influences multiple physiological systems, careful medical monitoring remains essential within approved therapeutic settings.
Overall, tesamorelin represents one of the most clinically validated peptides currently available, particularly for the management of HIV-associated visceral adiposity. Its endocrine mechanisms, metabolic effects, and influence on body composition are supported by high-quality clinical evidence. However, its broader application within regenerative medicine, aesthetic medicine, sports performance, or healthy ageing remains an active area of investigation. Continued large-scale clinical studies will be necessary to determine whether these emerging areas of research translate into safe and effective therapeutic applications beyond its currently approved indication.
- Falutz, J. et al. (2010) ‘Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomised placebo-controlled trial’, Journal of Clinical Endocrinology & Metabolism, 95(9), pp. 4291–4304.
- Stanley, T.L. et al. (2014) ‘Effects of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation’, The Lancet HIV, 1(2), pp. e66–e73.
- Stanley, T.L. et al. (2019) ‘Tesamorelin reduces liver fat and prevents progression of liver fibrosis in HIV-associated non-alcoholic fatty liver disease’, The Lancet HIV, 6(12), pp. e821–e830.
- Rahman, O.F., Lee, S.J. and Seeds, W.A. (2026) Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews, 10(1), e25.00236.
- DeFoor, M.T. and Dekker, T.J. (2025) Injectable Therapeutic Peptides—An Adjunct to Regenerative Medicine and Sports Performance? Arthroscopy, 41(2), pp. 150–152.
- Zhang, J., Linton, J.N. et al. (2025) Injectable Therapeutic Peptides: Applications in Regenerative Medicine and Sports Performance. American Journal of Sports Medicine. Narrative Review.
- U.S. Food and Drug Administration (2010) Prescribing Information for Tesamorelin (Egrifta®). Regulatory approval documentation.